Ernexia Therapeutics Files Q1 2025 10-Q
Ticker: ERNAW · Form: 10-Q · Filed: May 7, 2025 · CIK: 748592
| Field | Detail |
|---|---|
| Company | Ernexa Therapeutics Inc. (ERNAW) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financial-reporting
TL;DR
Ernexia Therapeutics filed its Q1 2025 10-Q. Check financials.
AI Summary
Ernexia Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Eterna Therapeutics Inc. and Brooklyn ImmunoTherapeutics, Inc., is based in Cambridge, MA. Financial details for the quarter are not explicitly detailed in this header information, but the filing covers the period from January 1, 2025, to March 31, 2025.
Why It Matters
This filing provides an update on Ernexia Therapeutics' financial performance and operational status for the first quarter of 2025, which is crucial for investors to assess the company's trajectory.
Risk Assessment
Risk Level: medium — As a biotechnology company, Ernexia Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-07 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Ernexia Therapeutics Inc. (company) — Filer of the 10-Q
- Eterna Therapeutics Inc. (company) — Former name of Ernexia Therapeutics Inc.
- Brooklyn ImmunoTherapeutics, Inc. (company) — Former name of Ernexia Therapeutics Inc.
- NTN BUZZTIME INC (company) — Former name of Ernexia Therapeutics Inc.
- 20250331 (date) — End of the reporting period
- 20250507 (date) — Filing date
- 001-11460 (dollar_amount) — SEC File Number
- 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (location) — Business Address
- 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127 (location) — Mail Address
FAQ
What were Ernexia Therapeutics' key financial results for the quarter ending March 31, 2025?
The provided header information does not contain specific financial results such as revenue, net income, or loss for the quarter ending March 31, 2025. A detailed review of the full 10-Q document is required for this information.
What is the primary business of Ernexia Therapeutics Inc.?
Ernexia Therapeutics Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When did Ernexia Therapeutics Inc. change its name from Eterna Therapeutics Inc.?
The company changed its name from Eterna Therapeutics Inc. on October 17, 2022.
What is the business address of Ernexia Therapeutics Inc.?
The business address for Ernexia Therapeutics Inc. is 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141.
What is the SEC file number for Ernexia Therapeutics Inc.?
The SEC file number for Ernexia Therapeutics Inc. is 001-11460.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Ernexa Therapeutics Inc. (ERNAW).